the publisher
About Doctor BPC-157
An independent editorial digest of the BPC-157 research literature — what the studies established, where the human evidence stops, and how access stands.
What this project is
Doctor BPC-157 is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site exists because most of what circulates online about BPC-157 is anecdote, sales copy, or both, and the actual literature — a large preclinical record, a coherent angiogenesis mechanism, and three small human pilots — deserves a careful, cited reading. We treat each finding the way an illuminated manuscript treats a passage: as something to read slowly, with its source named, rather than something to skim.
About the name
The word "doctor" in this site's name is editorial framing, not a claim about services. It signals the considered, literate register of a consulting reading-room — a place where a body of research is read closely and weighed — not a medical practice, a prescriber, or a storefront. There is no doctor you can see here, no clinical team, no consultation, and no prescription. The name describes a posture toward the literature, and nothing more.
We are explicit about this distinction because the gap between "a digest that reads the research" and "a clinic that offers treatment" is exactly the gap a reader needs to keep in view when the subject is an unapproved research peptide.
How we handle evidence
Every quantitative claim on this site — every dose, percentage, half-life, and sample size — maps to a numbered citation on the BPC-157 references page, drawn from PubMed, peer-reviewed journals, and FDA's own pages. We describe what was administered to which species at which dose by which route; we do not recommend doses for people, and we report the human evidence as the three small pilots it is. Where the record is thin, we mark the gap rather than fill it with inference.
We lead with findings and attribute them, and we keep the safety caveats — the overwhelmingly preclinical evidence, the single-investigator-source question, the unknown long-term oncologic picture, the regulatory status — in plain view. The aim is a reading you can trust precisely because it does not oversell.